When you study a rare cancer, an international community is priceless. Such is the case for Small Cell Carcinoma of the Ovary, Hypercalcemic Type ( #SCCOHT) Happy to engage in the wee small hrs of an Australian night & cheer on PhD student Natisha Field from our group sharing her research #digoxin 🧪
October 1, 2026 at 5:20 AM
When you study a rare cancer, an international community is priceless. Such is the case for Small Cell Carcinoma of the Ovary, Hypercalcemic Type ( #SCCOHT) Happy to engage in the wee small hrs of an Australian night & cheer on PhD student Natisha Field from our group sharing her research #digoxin 🧪
Happy to share this work on SMARCA4 and SCCOHT with Adela Rodríguez Hernández, Huma Rana, Judy Garber, Colin Young, Carolyn Horton, Linda Polfus, Brittany Borden, Miki Horiguchi, Magan Trottier, Jessica St. Laurent, and Jamie Weyandt. www.sciencedirect.com/science/arti...
SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort
To describe the cancer histories of individuals with a SMARCA4 germline pathogenic/likely pathogenic variant (gPV) obtained through clinical laborator…
www.sciencedirect.com
October 13, 2025 at 9:27 PM
Happy to share this work on SMARCA4 and SCCOHT with Adela Rodríguez Hernández, Huma Rana, Judy Garber, Colin Young, Carolyn Horton, Linda Polfus, Brittany Borden, Miki Horiguchi, Magan Trottier, Jessica St. Laurent, and Jamie Weyandt. www.sciencedirect.com/science/arti...
Wrapping up with a panel in the rare cancers session after my talk last week @ the Ovarian Cancer Australia Symposium 2025 in Melbourne beside my colleague @kylie-gorringe.bsky.social. Looking for new therapies to treat Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). #ovariancancer 🧪
September 1, 2025 at 6:36 AM
Wrapping up with a panel in the rare cancers session after my talk last week @ the Ovarian Cancer Australia Symposium 2025 in Melbourne beside my colleague @kylie-gorringe.bsky.social. Looking for new therapies to treat Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). #ovariancancer 🧪
Talented PhD student Natisha Field presenting her work on Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) @ the SCCOHT-SMARCA4 mtg in Canada. Very happy to be travelling Natisha's PhD journey with her. A 1st for me - 2 conferences on opposite sides of the world in one day/night! 🥰 🧪
May 26, 2025 at 1:12 AM
Talented PhD student Natisha Field presenting her work on Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) @ the SCCOHT-SMARCA4 mtg in Canada. Very happy to be travelling Natisha's PhD journey with her. A 1st for me - 2 conferences on opposite sides of the world in one day/night! 🥰 🧪
PhD student Natisha Field from our group presenting at her very first scientific conference in Canberra this week #ANZGOG2025ASM on her research discovering new molecular-based therapies to treat the rare #SmallCellCarcinomaOfTheOvaryHypercalcemicType. #RareCancers #OvarianCancer #SCCOHT #SWISNF 🧪
March 8, 2025 at 8:23 AM
PhD student Natisha Field from our group presenting at her very first scientific conference in Canberra this week #ANZGOG2025ASM on her research discovering new molecular-based therapies to treat the rare #SmallCellCarcinomaOfTheOvaryHypercalcemicType. #RareCancers #OvarianCancer #SCCOHT #SWISNF 🧪
I'll be speaking next week in Canberra at #ANZGOG (Australia & NZ Gynaecological Oncology Group), weaving my group's thoughts together on some of the most difficult to treat #ovariancancers and #endometriosis with focus on #ChromatinRemodelling. #OvarianClearCellCarcinoma #SCCOHT #SWI/SNF #ARID1A 🧪
March 2, 2025 at 12:34 AM
I'll be speaking next week in Canberra at #ANZGOG (Australia & NZ Gynaecological Oncology Group), weaving my group's thoughts together on some of the most difficult to treat #ovariancancers and #endometriosis with focus on #ChromatinRemodelling. #OvarianClearCellCarcinoma #SCCOHT #SWI/SNF #ARID1A 🧪
Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer
www.science.org/doi/10.1126/...
@thecleverslab.bsky.social
www.science.org/doi/10.1126/...
@thecleverslab.bsky.social
February 26, 2025 at 8:29 PM
Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer
www.science.org/doi/10.1126/...
@thecleverslab.bsky.social
www.science.org/doi/10.1126/...
@thecleverslab.bsky.social
Very cool work! Love seeing more SCCOHT research
January 10, 2025 at 6:21 PM
Very cool work! Love seeing more SCCOHT research
Paper stemming from my postdoctoral work on small cell carcinoma of the ovary, hypercalemic type (SCCOHT) is finally out in iScience! SMARCA4-mutant SCCOHT tumors have distinctly different enhancer regulation at super-enhancers and are extremely responsive to triptolide
www.cell.com/iscience/ful...
www.cell.com/iscience/ful...
Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type
Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare ovarian cancer affecting young females and is driven by the loss of both SWI/SNF ATPases SMARCA4 and SMARCA2. As loss of SWI/SNF alters enhancers, we hypothesized that super-enhancers, which regulate oncogene expression in cancer, are disparately impacted by SWI/SNF loss. We discovered differences between SWI/SNF occupancy at enhancers vs. super-enhancers. SCCOHT super-enhancer target genes were enriched in developmental processes, most notably nervous system development.
www.cell.com
January 10, 2025 at 4:27 PM
Paper stemming from my postdoctoral work on small cell carcinoma of the ovary, hypercalemic type (SCCOHT) is finally out in iScience! SMARCA4-mutant SCCOHT tumors have distinctly different enhancer regulation at super-enhancers and are extremely responsive to triptolide
www.cell.com/iscience/ful...
www.cell.com/iscience/ful...
Learning about small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) from @levinemd #AACROvCa17
https://www.nature.com/ng/journal/v46/n5/full/ng.2922.html
https://www.nature.com/ng/journal/v46/n5/full/ng.2922.html
Recurrent SMARCA4 mutations in small cell carcinoma of th...
Douglas Levine and colleagues identify recurrent inactiva...
www.nature.com
November 29, 2024 at 1:47 AM
Learning about small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) from @levinemd #AACROvCa17
https://www.nature.com/ng/journal/v46/n5/full/ng.2922.html
https://www.nature.com/ng/journal/v46/n5/full/ng.2922.html
We used cancer phenotype sex-specificity to enable more unbiased penetrance estimation of SMARCA4 PVs for SCCOHT tumours in the UKBiobank cohort and observed a 62% deficit of SMARCA4 PVs in females compared to males.
Just published in @GIMJournal
@UKCGG
Just published in @GIMJournal
@UKCGG
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an extremely rare, highly aggressive cancer (mean age of onset, 24 years). Nearly al…
sciencedirect.com
November 25, 2024 at 10:18 PM
We used cancer phenotype sex-specificity to enable more unbiased penetrance estimation of SMARCA4 PVs for SCCOHT tumours in the UKBiobank cohort and observed a 62% deficit of SMARCA4 PVs in females compared to males.
Just published in @GIMJournal
@UKCGG
Just published in @GIMJournal
@UKCGG
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
buff.ly
November 21, 2024 at 2:25 AM
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
Fascinating that ATPases SMARCA4 & SMARCA2 are both dysregulated in some rare & aggressive cancers by mutation & epigenetic silencing, respectively. We talk about epigenetic silencing of SMARCA2 & other things here: 10.1016/j.canlet.2024.217282 #SWI/SNF #SMARCA2 #Chromatin #OvarianCancer #SCCOHT
November 17, 2024 at 11:34 PM
Fascinating that ATPases SMARCA4 & SMARCA2 are both dysregulated in some rare & aggressive cancers by mutation & epigenetic silencing, respectively. We talk about epigenetic silencing of SMARCA2 & other things here: 10.1016/j.canlet.2024.217282 #SWI/SNF #SMARCA2 #Chromatin #OvarianCancer #SCCOHT
Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide https://www.biorxiv.org/content/10.1101/2023.09.08.556863v1
Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide https://www.biorxiv.org/content/10.1101/2023.09.08.556863v1
Purpose: Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare form of ovarian can
www.biorxiv.org
September 10, 2023 at 11:49 PM
Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide https://www.biorxiv.org/content/10.1101/2023.09.08.556863v1
Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide https://www.biorxiv.org/content/10.1101/2023.09.08.556863v1
Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide https://www.biorxiv.org/content/10.1101/2023.09.08.556863v1
Purpose: Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare form of ovarian can
www.biorxiv.org
September 10, 2023 at 11:49 PM
Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide https://www.biorxiv.org/content/10.1101/2023.09.08.556863v1